JAZZ Reports $1.1B Revenue, $4.43 EPS, +19% YoY; Zanidatamab sBLA Priority Review, PDUFA Aug 25, 2026; Xywav +18% Rev, 425 Net Adds
Jazz Pharmaceuticals, Inc. · PHARMACEUTICAL PREPARATIONS · Now $232.64
+8.9% in 7d after detection
Post-detection moves
1h
—
1d
+7.7%
3d
+6.4%
7d
+8.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS